SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO)

Historical Holders from Q3 2018 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
STRO on Nasdaq
Shares outstanding
84,733,230
Price per share
$0.81
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
53,391,796
Total reported value
$46,361,876
% of total 13F portfolios
0%
Share change
-2,191,668
Value change
-$1,653,962
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
85
Price from insider filings
$8.02
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Affinity Asset Advisors, LLC 7.8% $5,717,348 6,583,772 Affinity Healthcare Fund, LP 16 Oct 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 7.7% $5,579,959 6,488,324 Suvretta Capital Management, LLC 30 Jun 2025
MILLENNIUM MANAGEMENT LLC 5.6% $4,103,977 4,717,215 Millennium Management LLC 27 Jun 2025
VANGUARD GROUP INC 4.9% $3,580,268 4,115,250 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 2.5% -69% $1,820,284 -$3,524,654 2,092,281 -66% BlackRock, Inc. 30 Jun 2025
As of 30 Sep 2025, SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) has 85 institutional shareholders filing 13F forms. They hold 53,391,796 shares. of 84,733,230 outstanding shares (63%) .

Top 25 institutional shareholders own 59% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
SUVRETTA CAPITAL MANAGEMENT, LLC 7.7% 6,488,324 0% 0.17% $5,634,461
Kynam Capital Management, LP 6% 5,088,099 0% 0.33% $4,418,505
MILLENNIUM MANAGEMENT LLC 5.3% 4,524,350 -4.4% 0% $3,928,946
VANGUARD GROUP INC 4.3% 3,682,986 -11% 0% $3,196,832
ACADIAN ASSET MANAGEMENT LLC 4% 3,389,322 +11% 0.01% $2,941,000
Velan Capital Investment Management LP 3.7% 3,120,000 +2% 2.5% $2,709,408
TANG CAPITAL MANAGEMENT LLC 3.3% 2,828,717 +10% 0.09% $2,456,458
Merck & Co., Inc. 3.2% 2,723,509 0% 1% $2,365,095
Vestal Point Capital, LP 3.1% 2,600,000 0% 0.1% $2,257,840
Eversept Partners, LP 2.7% 2,291,313 -0.04% 0.15% $1,989,776
SAMSARA BIOCAPITAL, LLC 2.6% 2,196,814 0% 0.25% $1,907,713
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.4% 2,000,000 0% 0% $1,736,800
UBS Group AG 2.2% 1,845,839 +14% 0% $1,602,188
BlackRock, Inc. 2% 1,687,880 -20% 0% $1,465,755
RENAISSANCE TECHNOLOGIES LLC 1.7% 1,424,797 +56% 0% $1,237,294
GEODE CAPITAL MANAGEMENT, LLC 0.97% 820,948 +0.49% 0% $713,188
Affinity Asset Advisors, LLC 0.89% 752,722 0% 0.06% $653,664
JACOBS LEVY EQUITY MANAGEMENT, INC 0.53% 445,750 0% $387,089
DAFNA Capital Management LLC 0.52% 437,079 0% 0.09% $379,559
TWO SIGMA INVESTMENTS, LP 0.47% 396,785 +245% 0% $344,568
AQR CAPITAL MANAGEMENT LLC 0.42% 354,449 -65% 0% $307,804
Fisher Asset Management, LLC 0.42% 352,949 0% 0% $306,500
STATE STREET CORP 0.4% 342,652 0% 0% $297,559
Shay Capital LLC 0.37% 312,051 +20% 0.05% $270,985
ROYAL BANK OF CANADA 0.31% 258,876 +17% 0% $225,000

Institutional Holders of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 0 $0 -$40 0
2025 Q3 53,391,796 $46,361,876 -$1,653,962 $0.8684 85
2025 Q2 55,585,121 $39,680,994 -$3,651,760 $0.7139 100
2025 Q1 61,457,334 $39,985,995 -$10,841,278 $0.6506 113
2024 Q4 63,877,010 $117,530,449 -$7,341,386 $1.84 122
2024 Q3 62,516,525 $216,373,493 -$1,660,769 $3.46 130
2024 Q2 63,167,394 $185,075,121 +$25,139,085 $2.93 119
2024 Q1 53,412,221 $301,719,213 +$53,088 $5.65 116
2023 Q4 26,021 $111,630 +$5,663 $4.29 1
2023 Q3 55,996,442 $194,308,882 +$5,621,581 $3.47 108
2023 Q2 54,105,078 $251,585,947 +$2,181,883 $4.65 119
2023 Q1 53,720,779 $247,500,031 +$10,470,163 $4.62 114
2022 Q4 49,964,077 $403,698,901 +$6,293,558 $8.08 115
2022 Q3 50,375,230 $279,579,634 +$24,387,951 $5.55 109
2022 Q2 45,777,035 $237,610,254 +$14,941,497 $5.21 109
2022 Q1 40,824,094 $335,561,813 -$10,448,223 $8.22 106
2021 Q4 39,638,077 $589,831,817 -$2,506,160 $14.88 111
2021 Q3 39,164,701 $739,804,523 -$25,156,577 $18.89 116
2021 Q2 41,101,090 $764,056,023 -$71,811,227 $18.59 122
2021 Q1 44,015,379 $1,001,760,689 +$114,829,998 $22.76 136
2020 Q4 39,024,630 $847,232,796 +$176,816,006 $21.71 131
2020 Q3 28,627,158 $287,718,624 +$65,124,247 $10.05 84
2020 Q2 23,995,349 $186,221,799 +$97,624,858 $7.76 75
2020 Q1 11,865,381 $120,974,941 +$2,443,659 $10.20 58
2019 Q4 11,616,437 $127,772,633 +$7,088,067 $11.00 64
2019 Q3 10,079,029 $91,612,007 -$8,301,796 $9.09 58
2019 Q2 10,821,905 $122,728,440 +$6,666,674 $11.38 57
2019 Q1 10,236,199 $116,174,267 +$4,727,897 $11.39 48
2018 Q4 9,707,399 $87,234,000 -$2,783,067 $9.02 41
2018 Q3 9,086,875 $134,193,575 +$127,732,484 $15.00 32